Navigation Links
Going viral to target tumors
Date:3/5/2014

March 5, 2014, New York, NY A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors.

Published today in the journal Science Translational Medicine, the study evaluated a combination therapy in which the Newcastle disease virus (NDV), a bird virus not ordinarily harmful to humans, is injected directly into one of two melanoma tumors implanted in mice, followed by an antibody that essentially releases the brakes on the immune response. The researchers report that the combination induced a potent and systemically effective anti-tumor immune response that destroyed the non-infected tumor as well. Even tumor types that have hitherto proved resistant to checkpoint blockade and other immunotherapeutic strategies were susceptible to this combined therapy.

"Many patients have benefited from cancer immunotherapies," says Dmitriy Zamarin, a member of Ludwig's Collaborative Laboratory at Memorial Sloan Kettering Cancer Center (MSK) and lead author of the study together with James Allison of the MD Anderson Cancer Center in Houston, and Jedd Wolchok, Director of the Ludwig Collaborative Laboratory at MSK. "But they have not been effective for all patients, or against all cancer types, since most cancers can potently suppress immune responses. We want to extend the benefits of immunotherapies to more patients and optimize their use against a larger variety of cancers."

Zamarin and his colleagues found that an inflammatory immune response induced in the tumor by NDV primarily accounts for the efficacy of the therapy. The checkpoint blockade antibody used in this study binds CTLA-4, a molecule found on immune cells that acts like a brake (or "checkpoint") on the immune response. A version of this antibody is already used for cancer therapy, and it has proved potent in a clinical trial evaluating its combination with another immunotherapy as well.

The researchers noticed that when NDV was injected into a tumor implanted in mice, cancer-killing immune cells flooded into that tumor. "But we also found, to our surprise, that a similar infiltration of activated immune cells occurred in a distant tumor, one in which the virus was never detected," says Zamarin.

The researchers show that NDV infection alerts T cells of the immune system to the presence of cancer cells, which otherwise suppress immune surveillance and attack. Subsequent injection of the anti-CTLA-4 antibody dials up the incipient anti-tumor response so dramatically that it overcomes the tumor's immune suppression and destroys both NDV-exposed tumors and unexposed tumors. And the effect appears to be durable. When the same tumors are reintroduced into treated animals, they are swiftly eliminated.

Combining the two therapeutic strategies, Zamarin explains, overcomes the limitations of each. Oncolytic virotherapy has long been hindered by the immune system's tendency to disable systemically introduced viruses long before they can target tumors. The current study circumvented this problem by injecting NDV directly into the tumor.

Checkpoint blockade, meanwhile, has failed against tumors that suppress immune detection and attack. The researchers found that NDV prompted the cells of such tumors to betray themselves to the immune system when they informed it about the virus. As a consequence, the strategy even made colorectal and prostate tumors that were resistant to immunotherapy susceptible to checkpoint blockade.

The team also found that NDV could be used to boost the effects of an investigational immunotherapy known as adoptive T cell transfer, in which T cells are taken from patients, trained to recognize specific tumors and then reintroduced into their bodies. Adoptive transfer too has been hampered by the ability of tumors to suppress immune responses.

Pretreatment with NDV may similarly boost other immunotherapies. Additionally, Zamarin notes, NDV could be engineered to package and express immune factors that might further boost desirable elements of the anti-tumor response. The researchers are now working to expand production of NDV and devise protocols to evaluate their combination therapy in early stage clinical trials.


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related medicine news :

1. Yoga regulates stress hormones and improves quality of life for women with breast cancer undergoing
2. Study: Resilience in parents of children undergoing stem cell transplant
3. Most women undergoing surgery for vulvar cancer maintain healthy body image and sex life
4. Athletes “Toward Injury Prevention in Sports” TIPS Gets Going in Las Vegas
5. Going Back To Fitness Basics for Big Results: CrossFit Hub Releases New and Funky Exercise Clothing for Workouts
6. Las Vegas Fit Body Boot Camp The Lakes to Host Grand Opening Charity Event with Proceeds Going to Local Non-Profit, The First Tee of Southern Nevada
7. Salon Program Is Going on at Uniwigs.com
8. The Radiosurgery Society® Announces Initial Results from Ongoing, Multi-Center SRS/SBRT Patient Registry
9. Life Support Technologies Group Announces That Hyperbaric Medicine Shown to Benefit Breast Cancer Survivors Undergoing Breast Reconstruction
10. The Forbes Living Talk Show Is Going Green
11. oGoing Launches Android App for Small Business Social Media Marketing, Online Networking and Lead Generation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager ... are unaware of the plight of aphasia. In collaboration with the American Aphasia ... campaign. , The link between stroke and aphasia is relatively unknown, but through ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... 26, 2016 , ... W.S. Badger Co. Inc ., the maker of ... When Work Works Award for its use of effective workplace strategies to increase business ... project administered by the Families and Work Institute (FWI) and the Society for Human ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Connor ... women’s basketball as a partner for the Tamika Catchings Legacy Tour that ... the industry leader in hardwood basketball surfaces in all forms and levels of the ...
(Date:5/26/2016)... ... 26, 2016 , ... There are nearly 14.5 million people living with and ... On Sunday, June 5, 2016, communities around the world will gather to recognize these ... National Cancer Survivors Day® is an annual worldwide Celebration of Life that is held ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Hutchison China MediTech (Chi-Med) ... the highly lucrative global oncology and immunology markets. ... first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, ... partners. HCM,s profitable Chinese healthcare business continues to ... progress of the mid-to-late-stage pipeline during 2016-17 (including ...
(Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
Breaking Medicine Technology: